Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of oral 14C-PTC857 at steady state in healthy male volunteers
NL-OMON51552Phase 1Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of utreloxastat in amyotrophic lateral sclerosis (ALS) and neurological diseases, sponsored by PTC Therapeutics, Inc. Primary endpoints: Rates and routes of excretion and mass balance of total radioactivity, Pharmacokinetics of total radioactivity in whole blood and plasma and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)neurological diseases
Beyond the preview
Go deeper on NL-OMON51552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51552.